Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

Jonas Busch(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Barbara Erber(Charité - Universitätsmedizin Berlin), Robert W. Peters(Humboldt-Universität zu Berlin), Viktor Grünwald(Deutsche Schmerzgesellschaft), Christoph Seidel(Medizinische Hochschule Hannover), Ahmed Magheli(Johns Hopkins University), Kurt Miller(Charité - Universitätsmedizin Berlin), Frank Friedersdorff(Charité - Universitätsmedizin Berlin), Irena Goranova(Charité - Universitätsmedizin Berlin)
European Journal of Cancer
November 13, 2013
10.1016/j.ejca.2013.10.017
Cited by 20

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414